Mediators of allostasis and systemic toxicity in bipolar disorder

Physiology and Behavior

Volumn 106, Issue 1, 2012, Pages 46-50

  Grande, Iria ^a,b   Magalhães, Pedro V ^a   Kunz, Mauricio ^a   Vieta, Eduard ^b   Kapczinski, Flavio ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Allostatic load; Bipolar disorder; Glucocorticoids; Inflammation; Mitochondria; Neuroprogression; Neurotrophins; Oxidative stress

Indexed keywords

CATECHOLAMINE; GLUCOCORTICOID;

ALLOSTASIS; AMYGDALOID NUCLEUS; ARTICLE; BIPOLAR DISORDER; CATECHOLAMINE RELEASE; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; HUMAN RELATION; HYPOTHALAMUS; INFLAMMATION; NERVE CELL PLASTICITY; OXIDATIVE STRESS; PERSONAL EXPERIENCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; STRESS;

ALLOSTASIS; BIPOLAR DISORDER; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNITY; INFLAMMATION; MITOCHONDRIA; NEURONAL PLASTICITY; NEURONS; OXIDATIVE STRESS;

EID: 84857112386     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2011.10.029     Document Type: Article

References (83)

1. Merikangas K.R., Jin R., He J.P., Kessler R.C., Lee S., Sampson N.A., et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011, 68(3):241-251.
2. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293(20):2528-2530.
3. Soreca I., Frank E., Kupfer D.J. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis?. Depress Anxiety 2009, 26(1):73-82.
4. Angst F., Stassen H.H., Clayton P.J., Angst J. Mortality of patients with mood disorders: follow-up over 34-38years. J Affect Disord 2002, 68(2-3):167-181.
5. Altamura A.C., Serati M., Albano A., Paoli R.A., Glick I.D. Dell'Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci. 2011 Oct, 261(7):489-508.
6. Kilbourne A.M., Post E.P., Nossek A., Drill L., Cooley S., Bauer M.S. Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. Psychiatr Serv 2008, 59(7):760-768.
7. Sylvia L.G., Nierenberg A.A., Stange J.P., Peckham A.D., Deckersbach T. Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. J Psychiatr Pract 2011, 17(3):224-232.
8. Leboyer M., Kupfer D.J. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry 2010, 71(12):1689-1695. Epub 2010/12/31.
9. Magalhaes P, Kapczinski F, Nierenberg A, Deckersbach T, Weisinger D, Dodd S, et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatrica Scandinavica.
10. Mur M., Portella M.J., Martinez-Aran A., Pifarre J., Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry 2008, 69(5):712-719.
11. Lopez-Jaramillo C., Lopera-Vasquez J., Gallo A., Ospina-Duque J., Bell V., Torrent C., et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010, 12(5):557-567.
12. Gualtieri C.T., Johnson L.G. Age-related cognitive decline in patients with mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(4):962-967.
13. Panza F., Frisardi V., Capurso C., Imbimbo B.P., Vendemiale G., Santamato A., et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 2010, 21(3):691-724.
14. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Traniontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32(4):675-692.
15. Juster R.P., McEwen B.S., Lupien S.J. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev 2010, 35(1):2-16.
16. McEwen B.S. Interacting mediators of allostasis and allostatic load: towards an understanding of resilience in aging. Metabolism-Clinical and Experimental 2003, 52(10):10-16.
17. McEwen B.S., Stellar E. Stress and the individual - mechanisms leading to disease. Arch Intern Med 1993, 153(18):2093-2101.
18. McEwen B.S. Protective and damaging effects of stress mediators. N Engl J Med 1998, 338(3):171-179.
19. McEwen B.S. Protection and damage from acute and chronic stress - allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Biobehavioral stress response: protective and damaging effects 2004, 1-7. R. Yehuda, B. McEwen (Eds.).
20. Karlamangla A.S., Singer B.H., McEwen B.S., Rowe J.W., Seeman T.E. Allostatic load as a predictor of functional decline: MacArthur studies of successful aging. J Clin Epidemiol 2002, 55(7):696-710.
21. Karlamangla A.S., Singer B.H., Greendale G.A., Seeman T.E. Increase in epinephrine excretion is associated with cognitive decline in elderly men: MacArthur studies of successful aging. Psychoneuroendocrinology 2005, 453-460. England.
22. Karlamangla A.S., Singer B.H., Seeman T.E. Reduction in allostatic load in older adults is associated with lower all-cause mortality risk: MacArthur studies of successful aging. Psychosom Med 2006, 68(3):500-507.
23. Seeman T.E., McEwen B.S., Singer B.H., Albert M.S., Rowe J.W. Increase in urinary cortisol excretion and memory declines: MacArthur studies of successful aging. J Clin Endocrinol Metab 1997, 82(8):2458-2465. Epub 1997/08/01.
24. Seeman T.E., Crimmins E. Social environment effects on health and aging: integrating epidemiologic and demographic approaches and perspectives. Ann N Y Acad Sci 2001, 954:88-117. Epub 2002/01/19.
25. Seeman T.E., Crimmins E., Huang M.H., Singer B., Bucur A., Gruenewald T., et al. Cumulative biological risk and socio-economic differences in mortality: MacArthur studies of successful aging. Soc Sci Med 2004, 58(10):1985-1997.
26. Gruenewald T.L., Seeman T.E., Karlamangla A.S., Sarkisian C.A. Allostatic load and frailty in older adults. J Am Geriatr Soc 2009, 57(9):1525-1531.
27. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V.S., Kauer-Sant'Anna M., Klamt F., et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010, 15(8):784-786.
28. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V.S., Kauer-Sant'Anna M., Klamt F., et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011, 45(2):156-161.
29. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009, 12(4):447-458.
30. Andreazza A.C., Kapczinski F., Kauer-Sant'Anna M., Walz J.C., Bond D.J., Goncalves C.A., et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 2009, 34(4).
31. Lewandowski K.E., Cohen B.M., Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med 2011, 41(2):225-241.
32. Cacilhas A.A., Magalhaes P.V.D., Cereser K.M., Walz J.C., Weyne F., Rosa A.R., et al. Bipolar disorder and age-related functional impairment. Revista Brasileira De Psiquiatria. 2009, 31(4):354-357.
33. Magalhães P.V., Jansen K., Pinheiro R.T., Klamt F., Teixeira A.L., da Silva R.A., Kapczinski F. Systemic toxicity in early-stage mood disorders. J Psychiatr Res. 2011 Oct, 45(10):1407-1409.
34. Daban C., Vieta E., Mackin P., Young A.H. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005, 28(2):469.
35. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70(8):1078-1090.
36. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3):804-817.
37. McEwen B.S. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008, 583(2-3):174-185.
38. Jankord R., Herman J.P. Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. Stress, neurotransmitters, and hormones: neuroendocrine and genetic mechanisms 2008, 64-73. R. Kvetnansky, G. Aguilera, D. Goldstein, D. Jezova, O. Krizanova, E.L. Sabban (Eds.).
39. Felitti V.J., Anda R.F., Nordenberg D., Williamson D.F., Spitz A.M., Edwards V., et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults - the adverse childhood experiences (ACE) study. Am J Prev Med 1998, 14(4):245-258.
40. Phillips M.L., Vieta E. Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr Bull 2007, 33(4):893-904.
41. Korte S.M., Koolhaas J.M., Wingfield J.C., McEwen B.S. The Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and disease. Neurosci Biobehav Rev 2005, 29(1):3-38.
42. Villeda S.A., Luo J., Mosher K.I., Zou B., Britschgi M., Bieri G., et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011, 477(7362):90-94.
43. Snyder J.S., Soumier A., Brewer M., Pickel J., Cameron H.A. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476(7361):458-461.
44. Hanson N.D., Owens M.J., Nemeroff C.B. Depression, Antidepressants, and Neurogenesis: A Critical Reappraisal. Neuropsychopharmacology 2011, Sep 21. doi:10.1038/npp.2011.220. [Epub ahead of print].
45. Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: Are we mistaking the scaffolding for the building?. Neuropharmacology. 2012 Jan, 62(1):21-34.
46. Okuda S., Roozendaal B., McGaugh J.L. Glucocorticoid effects on object recognition memory require training-associated emotional arousal. Proc Natl Acad Sci USA 2004, 101(3):853-858.
47. Mateo J.M. Inverted-U shape relationship between cortisol and learning in ground squirrels. Neurobiol Learn Mem 2008, 89(4):582-590.
48. Prager E.M., Johnson L.R. Stress at the synapse: signal transduction mechanisms of adrenal steroids at neuronal membranes. Sci Signal 2009, 2(86):re5.
49. Gould E., Woolley C.S., McEwen B.S. Short-term glucocorticoid manipulations affect neuronal morphology and survival in the adult dentate gyrus. Neuroscience 1990, 37(2):367-375.
50. Sorrells S.F., Caso J.R., Munhoz C.D., Sapolsky R.M. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 2009, 64(1):33-39.
51. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex i activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010, 67(4):360-368.
52. Cataldo A.M., McPhie D.L., Lange N.T., Punzell S., Elmiligy S., Ye N.Z., et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 2010, 177(2):575-585.
53. Andreazza A.C., Kauer-Sant'Anna M., Frey B.N., Bond D.J., Kapczinski F., Young L.T., et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111(2-3):135-144.
54. Frey B.N., Martins M.R., Petronilho F.C., Dal-Pizzol F., Quevedo J., Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 2006, 8(3):275-280.
55. Valvassori S.S., Rezin G.T., Ferreira C.L., Moretti M., Goncalves C.L., Cardoso M.R., et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with D-amphetamine. J Psychiatr Res 2010, 44(14):903-909.
56. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 2008, 3(4):203-217. Epub 2008/08/19.
57. Du J., Wang Y., Hunter R., Wei Y., Blumenthal R., Falke C., et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci USA 2009, 106(9):3543-3548.
58. Du J., McEwen B., Manji H.K. Glucocorticoid receptors modulate mitochondrial function: a novel mechanism for neuroprotection. Commun Integr Biol 2009, 2(4):350-352. Epub 2009/09/02.
59. Munck A., Guyre P.M. Glucocorticoid physiology, pharmacology and stress. Adv Exp Med Biol 1986, 196:81-96. Epub 1986/01/01.
60. Munck A., Naray-Fejes-Toth A. The ups and downs of glucocorticoid physiology. Permissive and suppressive effects revisited. Mol Cell Endocrinol 1992, 90(1):C1-C4.
61. Wiegers G.J., Croiset G., Reul J.M., Holsboer F., de Kloet E.R. Differential effects of corticosteroids on rat peripheral blood T-lymphocyte mitogenesis in vivo and in vitro. Am J Physiol 1993, 265(6 Pt 1):E825-E830. Epub 1993/12/01.
62. Drexhage R.C., Knijff E.M., Padmos R.C., van der Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010, 10(1):59-76.
63. Drexhage R.C., van der Heul-Nieuwenhuijsen L., Padmos R.C., van Beveren N., Cohen D., Versnel M.A., et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010, 13(10):1369-1381.
64. Padmos R.C., Van Baal G.C.M., Vonk R., Wijkhuijs A.J.M., Kahn R.S., Nolen W.A., et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch Gen Psychiatry 2009, 66(9):957.
65. Magalhães P., Dean O., Bush A., Copolov D., Malhi G., Kohlmann K., et al. Dimensions of improvement in a clinical trial of n-acetyl cysteine for bipolar disorder. Acta Neuropsychiatrica. 2011, 23(2):87-88.
66. Berk M., Brnabic A., Dodd S., Kelin K., Tohen M., Malhi G.S., et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011, 13(1):87-98. Epub 2011/02/16.
67. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Brietzke E., Vazquez G.H., Vieta E., et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1366-1371.
68. Kapczinski F., Fernandes B.S., Kauer-Sant'Anna M., Gama C.S., Yatham L.N., Berk M. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica. 2009, 21(6):272-274.
69. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004, 5(1):11-25.
70. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009, 5(6):311-322.
71. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59(12):1116-1127.
72. Manji H.K., Moore G.J., Rajkowska G., Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000, 5(6):578-593.
73. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10(9):1089-1093.
74. Kapczinski F., Frey B.N., Andreazza A.C., Kauer-Sant'Anna M., Cunha A.B.M., Post R.M. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Revista Brasileira De Psiquiatria. 2008, 30(3):243-245.
75. Fernandes B.S., Gama C.S., Cereser K.M., Gomes F.A., Kunz M., Colpo G.D., et al. Brain-derived neutrotrophic in mania, depression, and euthymia in bipolar disorders: a systematic review and meta-analysis. Bipolar Disord 2010, 12:19.
76. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009, 12(4):441-445.
77. Magalhães P., Jansen K., Pinheiro R., Colpo G., da Motta L., Klamt F., et al. Peripheral oxidative damage in early-stage mood disorders: a nested population-based case-control study 2012.
78. McGorry P.D., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006, 40(8):616-622.
79. Berk M., Conus P., Lucas N., Hallam K., Malhi G.S., Dodd S., et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007, 9:671-678.
80. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007, 100(1-3):279-281.
81. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Frey B.N., Grassi-Oliveira R., Colom F., et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009, 9(7):957-966. Epub 2009/07/11.
82. Scott J., Paykel E., Morriss R., Bentall R., Kinderman P., Johnson T., et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders - randomised controlled trial. Br J Psychiatry 2006, 188:313-320.
83. Reinares M., Colom F., Rosa A.R., Bonnin C.M., Franco C., Sole B., et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord 2010, 123(1-3):81-86.